Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16481681 | 0.86 | TAAR1 (0.44) | HTR2ATAAR1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3152528 | 0.81 | TAAR1 (0.44) | HTR2ATAAR1HTR2CSMN1; SMN2 | |
| SCHEMBL333776 | 0.78 | HTR2A (0.46) | HTR2ATAAR1HTR2CSMN1; SMN2 | |
| SCHEMBL27772997 | 0.74 | PDE4A (0.47) | HTR2ATAAR1HTR2CKDM4EALDH1A1 | |
| SCHEMBL27869012 | 0.72 | PYCR1 (0.49) | HTR2ATAAR1HTR2CKDM4E | |
| SCHEMBL10667947 | 0.72 | MAPT (0.48) | SMN1; SMN2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL12978347 | 0.72 | MEN1 (0.47) | HTR2ATAAR1KDM4EALDH1A1 | |
| SCHEMBL15701378 | 0.72 | HTT (0.37) | — | |
| SCHEMBL27785360 | 0.71 | CYP1A2 (0.41) | HTR2ATAAR1HTR2CALDH1A1 | |
| SCHEMBL2862226 | 0.70 | L3MBTL1 (0.50) | HTR2ATAAR1HTR2CSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| EP-2203454-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. Organon (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | HTR2A 10/4885TAAR1 103/4885HTR2C 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.